Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

Boehringer Ingelheim Earns Breakthrough Therapy Designation for Pustular Psoriasis Drug

Boehringer Ingelheim Earns Breakthrough Therapy Designation for Pustular Psoriasis Drug

The FDA granted breakthrough therapy designation to Boehringer Ingelheim’s Spevigo (spesolimab) as a treatment to prevent flares in adults with generalized pustular psoriasis (GPP).

GPP is a rare and systemic skin disease characterized by flares of painful, sterile pustules eruptions across the body, and can potentially be life-threatening.

The designation was granted based on the results of a Phase 2 clinical trial demonstrating that spesolimab can prevent flares in adolescents and adults with GPP up to 48 weeks.

The breakthrough therapy designation speeds the development and review of a medicine that may offer substantial improvement compared to the available standard of care for the treatment of a serious or life-threatening disease.

About Spevigo (spesolimab)

Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody medication used for the treatment of generalized pustular psoriasis (GPP). It is an interleukin-36 receptor (IL1RL2/IL1RAP) antibody.

It was approved for medical use in the United States in September 2022, and in European Union in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

May 5, 2023

https://www.fdanews.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies